These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31679761)

  • 1. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S; Karlström C; Höglund P
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-Mediated Platelet Refractoriness.
    Schmidt AE; Refaai MA; Coppage M
    Am J Clin Pathol; 2019 Mar; 151(4):353-363. PubMed ID: 30285067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion.
    Belizaire R; Makar RS
    Transfus Med Rev; 2020 Oct; 34(4):242-249. PubMed ID: 33129606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
    Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
    Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
    Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The definition of refractoriness to platelet transfusions.
    Bishop JF; Matthews JP; Yuen K; McGrath K; Wolf MM; Szer J
    Transfus Med; 1992 Mar; 2(1):35-41. PubMed ID: 1308461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
    Vo P; Purev E; West KA; McDuffee E; Worthy T; Cook L; Hawks G; Wells B; Shalabi R; Flegel WA; Adams SD; Reger R; Aue G; Tian X; Childs R
    Br J Haematol; 2020 May; 189(3):551-558. PubMed ID: 32086819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
    Murphy MF; Brozovic B; Murphy W; Ouwehand W; Waters AH
    Transfus Med; 1992 Dec; 2(4):311-8. PubMed ID: 1339584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and management of platelet transfusion refractoriness.
    Novotny VM
    Vox Sang; 1999; 76(1):1-13. PubMed ID: 9933848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory response to platelet transfusion therapy.
    Eisenberg S
    J Infus Nurs; 2010; 33(2):89-97. PubMed ID: 20228646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet transfusion refractoriness and anti-HLA immunization.
    Blandin L; Dougé A; Fayard A; Bay JO; Berlie G; Pereira B; Lemal R; Rouzaire P
    Transfusion; 2021 Jun; 61(6):1700-1704. PubMed ID: 33709433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion.
    Peña JR; Saidman SL; Girouard TC; Meister E; Dzik WH; Makar RS
    Am J Hematol; 2014 Sep; 89(9):E133-7. PubMed ID: 24816643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.